RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $13 to $14.
Read original at benzingaFilings · News reference
U.S. District Court Granted Preliminary Approval Of CorMedix Derivative Settlement On July 24; Final Hearing Set For September 23
-SEC Filing
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 8:24 PM
- Checked
- Aug 7, 2026, 8:24 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
CorMedix Stock Jumps on Strong DefenCath Sales
CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.
Read original at benzingaAccelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday
Nasdaq Composite gained 200 points on Thursday, while Accelerant Holdings (NYSE: ARX) rose 44.2% after being acquired by Thoma Bravo and reporting strong Q2 results. Other top gainers include Omeros Corp (NASDAQ: OMER), CorMedix Inc (NASDAQ: CRMD), and Hyliion Holdings Corp (NYSE: HYLN).
Read original at benzingaFull Transcript: Cormedix Q2 2026 Earnings Call
On Thursday, Cormedix (NASDAQ:CRMD) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data
Read original at benzinga